SCHEMBL1627735

SCHEMBL1627735

CCOC(=O)C1=C(O)c2ccncc2C(C)(C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
SPR P35270 1/20 0.38
MMP13 P45452 1/20 0.38
MAPT P10636 6/20 0.37
ALDH1A1 P00352 6/20 0.37
KDM4E B2RXH2 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
HPGD P15428 3/20 0.37
LMNA P02545 2/20 0.37
PKM P14618 2/20 0.37
ATM Q13315 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CDC7 O00311 2/20 0.37
DBF4 Q9UBU7 2/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 1/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626562 0.82 MAPT (0.48) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1625637 0.78 TDP2 (0.41) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1626427 0.78 KMT2A (0.42) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1626913 0.78 SPR (0.52) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1625402 0.77 SPR (0.46) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1627382 0.76 MAPT (0.43) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1627512 0.76 EGLN1 (0.46) SPRFGFR1FLT1FGFR3
SCHEMBL1626468 0.75 SPR (0.59) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1624395 0.75 SPR (0.45) SPRMAPTALDH1A1KDM4EMEN1
SCHEMBL1627014 0.75 SPR (0.45) SPRMAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN KDM5A 1161/4885KDM5B 1092/4885SPR 754/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN KDM5A 1161/4885KDM5B 1092/4885SPR 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.